stoxline Quote Chart Rank Option Currency Glossary
BioLineRx Ltd. (BLRX)
1.52  0.07 (4.83%)    12-01 15:59
Open: 1.45
High: 1.54
Volume: 190,170
Pre. Close: 1.45
Low: 1.44
Market Cap: 113(M)
Technical analysis
2023-12-01 4:18:37 PM
Short term     
Mid term     
Targets 6-month :  1.95 1-year :  2.25
Resists First :  1.67 Second :  1.92
Pivot price 1.54
Supports First :  1.25 Second :  1.03
MAs MA(5) :  1.45 MA(20) :  1.53
MA(100) :  1.6 MA(250) :  1.24
MACD MACD :  -0.1 Signal :  -0.1
%K %D K(14,3) :  17 D(3) :  13.7
RSI RSI(14): 48.9
52-week High :  2.52 Low :  0.55
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ BLRX ] has closed above bottom band by 43.4%. Bollinger Bands are 15.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 1.48 - 1.49 1.49 - 1.5
Low: 1.35 - 1.36 1.36 - 1.37
Close: 1.44 - 1.45 1.45 - 1.46
Company Description

BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for the treatment of solid tumors and acute myeloid leukemia. It is also developing AGI-134, an immuno-oncology agent, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of skin lesions. The company has collaboration agreement with MSD for the cancer immunotherapy field; MD Anderson Cancer Center to investigate the combination of Motixafortide with KEYTRUDA (pembrolizumab) in pancreatic cancer; and licensing arrangement with Perrigo Company plc for over-the-counter sale of BL-5010. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.

Headline News

Mon, 20 Nov 2023
BioLineRx Reports Third Quarter 2023 Financial Results and ... - PR Newswire

Mon, 13 Nov 2023
BioLineRx to Report Third Quarter 2023 Results on November 20 ... - Yahoo Finance

Tue, 07 Nov 2023
Biolinerx shares climb after $270M+ motixafortide deal in Asia with ... - BioWorld Online

Thu, 12 Oct 2023
BioLineRx Announces Closing of Exclusive License Agreement to ... - PR Newswire

Thu, 28 Sep 2023
BioLineRx Announces Encouraging Data from Pilot Phase of Phase ... - PR Newswire

Mon, 18 Sep 2023
Assessing BioLineRx As A Buy After Drug Approval (NASDAQ:BLRX) - Seeking Alpha

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 72 (M)
Shares Float 874 (M)
Held by Insiders 0 (%)
Held by Institutions 5.2 (%)
Shares Short 491 (K)
Shares Short P.Month 2,560 (K)
Stock Financials
EPS -0.75
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -36.8 %
Return on Equity (ttm) -152.9 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -0.54
Qtrly Earnings Growth 0 %
Operating Cash Flow -33 (M)
Levered Free Cash Flow -23 (M)
Stock Valuations
PE Ratio -2.02
PEG Ratio 0
Price to Book value 151
Price to Sales 0
Price to Cash Flow -3.28
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android